Fundraising Fox
Amgen
NASDAQ: AMGNThousand Oaks, US · Founded 1980 · Delaware corporation · 6 known investors
Find your way into Amgen
Each arrow is one introduction. Sign up to fill in the first one.
Ask Desmond Padhi to introduce you to Peter H. Griffith
You →Desmond · together at Amgen →Peter
Ask Jamie Chen to introduce you to Nancy A. Grygiel
You →Jamie · together at Mylan →Nancy
Ask Sam Okafor to introduce you to Sean E. Harper
You →Sam · together at Westlake Village BioPartners →Sean
- David M. Reese172 people can intro you
- Stuart A. Tross73 people can intro you
- Kave Niksefat68 people can intro you
Sign up to find every way you can get introduced to Amgen
- Your email: who you already know at Amgen, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amgen team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Founders & leadership
Amgen was founded in 1980 by William K. Bowes and George B. Rathmann.
Investors · 6
How we know: Asset Management Company's portfolio page · Not right? Tell us
How we know: Mayfield Fund's portfolio page · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements▶$2.5BofferedJan 2015 · 34 investors · BiotechnologyRule 506(b)
- David PiacquadExecutive Officer
- Francois de CarbonnelDirector
- Brian M. McNameeExecutive Officer
- Tyler JacksDirector
- Ronald D. SugarDirector
- Robert A. BradwayExecutive Officer, Director
- David J. ScottExecutive Officer
- Madhavan BalachandranExecutive Officer
- Stuart A. TrossExecutive Officer
- David W. MelineExecutive Officer
- Sean E. HarperExecutive Officer
- Rebecca M. HendersonDirector
- Judith PelhamDirector
- Vance D. CoffmanDirector
- David BaltimoreDirector
- Cynthia M. PattonExecutive Officer
- Greg C. GarlandDirector
- Frank C. HerringerDirector
- Frank J. Biondi, Jr.Director
- Robert A. EckertDirector
- Anthony C. HooperExecutive Officer
- R. Sanders WilliamsDirector
- Offering amount
- $2.5B
- Minimum investment
- $250K
- Sales commissions
- $750K
- Placement agents
- Deutsche Bank Securities Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Banc of America Securities LLC, Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated
- First sale
- Sep 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Amgen mafia →50 people who came through Amgen went on to found or lead other companies.
Acquisitions · 4
Early investors' stakes continue via these dealsAmgen is a biopharmaceutical company that develops and manufactures therapeutics targeting oncology, cardiovascular disease, inflammation, bone health, neuroscience, and other serious illnesses. The company operates globally with manufacturing facilities across the United States, Europe, and Asia, serving patients and healthcare providers worldwide.
Five Prime Therapeutics was a clinical-stage biotech in South San Francisco developing protein- and antibody-based immuno-oncology therapies, including the FGFR2b-targeting antibody bemarituzumab for gastric cancer.
Micromet was a biopharmaceutical company based in Rockville, MD and Munich, Germany that developed antibody-based cancer therapies using its proprietary BiTE (Bispecific T-cell Engager) platform, including lead candidate blinatumomab.
Nuevolution was a Copenhagen-based biopharmaceutical company developing small-molecule drugs for oncology and chronic inflammatory diseases using its proprietary DNA-encoded chemical library platform, Chemetics.
Frequently asked questions
- What does Amgen do?
- Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
- Who founded Amgen?
- Amgen was founded by William K. Bowes, George B. Rathmann in 1980.
- Who are Amgen's investors?
- Amgen's investors include Asset Management Company, BOM, Boulder Ventures, Mayfield Fund, Ridgeback Capital, Sunstone Capital.
- Where is Amgen headquartered?
- Amgen is headquartered in Thousand Oaks, US.